Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge

Journal of Virology

Volumn 72, Issue 4, 1998, Pages 3390-3393

  O'Neal, Christine M ^a   Clements, John D ^b   Estes, Mary K ^a   Conner, Margaret E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; IMMUNOGLOBULIN G; RECOMBINANT VACCINE;

ANIMAL CELL; ARTICLE; CHOLERA; ESCHERICHIA COLI; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROTAVIRUS; VIRULENCE; VIRUS PARTICLE;

EID: 0031900149     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.4.3390-3393.1998     Document Type: Article

References (16)

1. Clements, J. D., and R. A. Finkelstein. 1979. Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect. Immun. 24:760-769.
2. Clements, J. D., N. M. Hartzog, and F. L. Lyon. 1988. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6:269-277.
3. Crawford, S. E., M. Labbe, J. Cohen, M. H. Burroughs, Y. Zhou, and M. K. Estes. 1994. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J. Virol. 68:5945-5952.
4. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617-1623.
5. Dickinson, B. L., and J. D. Clements. 1996. Use of Escherichia coli heat-labile enterotoxin as an oral adjuvant, p. 73-87. In H. Kiyono, P. L. Ogra, and J. R. McGhee (ed.), Mucosal vaccines. Academic Press, Inc., San Diego, Calif.
6. Douce, G., C. Turcotte, I. Cropley, M. Roberts, M. Pizza, M. Domenghini, R. Rappuoli, and G. Dougan. 1995. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 92:1644-1648.
7. Feng, N., J. W. Burns, L. Bracy, and H. B. Greenberg. 1994. Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus. J. Virol. 68:7766-7773.
8. Franco, M. A., and H. B. Greenberg. 1995. Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice. J. Virol. 69:7800-7806.
9. Giannelli, V., M. R. Fontana, M. M. Giuliani, D. Guangcai, R. Rappuoli, and M. Pizza. 1997. Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop. Infect. Immun. 65:331-334.
10. Institute of Medicine. 1986. New vaccine development. Establishing priorities, p. 308-318. In Diseases of importance in developing countries, vol. 2. National Academy Press, Washington, D.C.
11. Katz, J. M., X. Lu, J. C. Galphin, and J. D. Clements. 1996. Heat labile enterotoxin from Escherichia coli as an adjuvant for oral influenza vaccination, p. 292-297. In L. E. Brown. A. W. Hampson, and R. G. Webster (ed.), Options for the control of influenza, vol. 3. Elsevier Science, New York, N.Y.
12. Levine, M. M., J. B. Kaper, R. E. Black, and M. L. Clements. 1983. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47:510-550.
13. Lobet, Y., C. W. Cluff, and W. Cieplak. 1991. Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin. Infect. Immun. 59:2870-2879.
14. O'Neal, C. M., S. E. Crawford, M. K. Estes, and M. E. Conner. 1997. Rotavirus virus-like particles administered mucosally induce protective immunity. J. Virol. 71:8707-5717.
15. Oplinger, M. L., S. Baqar, A. F. Trofa, J. D. Clements, P. Gibbs, G. Pazzaglia, A. L. Bourgeois, and D. A. Scott 1997. Safety and immunogenicity in volunteers of a new candidate oral mucosal adjuvant, LT(R192G), abstr. G-10, p. 193. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
16. Yamamoto, S., Y. Takeda, M. Yamamoto, H. Kurazono, K. Imaoka, M. Yamamoto, K. Fujihasbi, M. Noda, H. Kiyono, and J. R. McGhee. 1997. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrhoea-genicity but retain adjuvanticity. J. Exp. Med. 185:1203-1210.